mAb Development

Nov 01, 2016
BioPharm International
The development of mAb formulations poses challenges at the manufacturing, stability, analytical, and administration levels.
Oct 06, 2016
By BioPharm International Editors
The companies are collaborating on the commercialization of two biosimilar candidates in the US and Canada.
Oct 06, 2016
Results from the Phase III POLLUX trial with Janssen’s Darzalex showed that the drug was effective at reducing disease progression in patients with relapsed or refractory multiple myeloma.
Oct 03, 2016
By BioPharm International Editors
Allergan entered into a licensing agreement with AstraZeneca for MEDI2070, an anti-IL-23 monoclonal antibody in phase IIB development for the treatment of patients with moderate-to-severe Crohn’s disease.
Oct 01, 2016
BioPharm International
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
Sep 01, 2016
BioPharm International
This study offers a strategy for stabilization of biotherapeutics for long-term frozen storage in PBS-based formulations.
Sep 01, 2016
BioPharm International
Industry experts discuss best practices for selecting a separation technology.
Sep 01, 2016
BioPharm International
The authors outline cell-line development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.
Aug 15, 2016
By BioPharm International Editors
Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.
Aug 01, 2016
BioPharm International
The study demonstrates a systematic approach to stabilize PBS-formulated mAbs against freeze-thaw degradation.
native1_300x100
lorem ipsum